Physician profile
Thaddeus R Temple
NPI 1801854161
$3,073.94
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $743 · 2021: $647 · 2022: $370 · 2023: $469 · 2024: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $739.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $924.08 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $329.68 | 2019-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.18 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $201.44 | 2019-2024 | Eliquis |
| Novo Nordisk INC | $184.86 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $163.15 | 2019-2022 | |
| Abbott Laboratories | $136.42 | 2023-2024 | Freestyle Libre |
| Pfizer INC. | $123.63 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $99.42 | 2019-2021 | |
| Exact Sciences Corporation | $95.55 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $88.17 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $84.01 | 2019-2022 | |
| Astellas Pharma US INC | $77.64 | 2019-2021 | |
| Esperion Therapeutics, INC. | $70.33 | 2021-2022 | |
| Amgen INC. | $62.55 | 2019-2024 | Repatha, Otezla |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $59.70 | 2019-2020 | |
| Allergan, INC. | $38.84 | 2019 | |
| Amarin Pharma, INC. | $27.25 | 2020 | |
| Abbvie INC. | $26.73 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.32 | 2022 | |
| Currax Pharmaceuticals LLC | $14.26 | 2024 | Contrave, Onzetra Xsail |
| Janssen Pharmaceuticals, INC | $13.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thaddeus Temple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.